Theradiag

The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products. 

The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.

NEW YORK (GenomeWeb News) – Diagnostic firm Theradiag today announced a partnership with French organizations to develop diagnostic and theranostic tools for rheumatoid arthritis.

NEW YORK (GenomeWeb News) – French molecular diagnostics firm Theradiag announced Monday that its microRNA diagnostics subsidiary Prestizia has inked two deals to develop HIV/AIDS assays in collaboration with the French National Center for Scientific Research (CNRS).

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Theradiag this week announced several management changes in line with the strategic organization of the company into two divisions following last year's acquisition of microRNA technology firm Prestizia.

NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

After buying small microRNA firm Prestizia last June, France's Theradiag is moving forward in development of several miRNA tests in the HIV disease area, as well as two companion diagnostic projects for experimental therapies, one for HIV and another for obesity under a $1.6 mill

NEW YORK (GenomeWeb News) – Theradiag today announced that Oséo has provided it €1.2 million ($1.6 million) to develop new diagnostic kits as part the French firm's participation in a project to develop RNA-targeting therapeutics and diagnostics aimed at HIV/AIDS and obesity.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.